{"transactions":[{"id":1263952,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-18T21:20:28.000Z","date":"2025-02-13","kind":"sale","planned":true,"acquired":false,"shares":2227,"price":1.42,"value":3162.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024."}],"balance_after":126625,"source":{"system":"sec-edgar","filing":"0001415889-25-004406","document":"form4-02182025_090225.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925004406/form4-02182025_090225.xml","form_type":"4"}},{"id":1271853,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-12T21:29:05.000Z","date":"2025-02-10","kind":"sale","planned":true,"acquired":false,"shares":2554,"price":1.37,"value":3498.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.33 to $1.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":128852,"source":{"system":"sec-edgar","filing":"0001415889-25-003734","document":"form4-02122025_090258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925003734/form4-02122025_090258.xml","form_type":"4"}},{"id":1278838,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-07T21:35:05.000Z","date":"2025-02-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":1180,"price":1.5,"value":1770.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":131406,"source":{"system":"sec-edgar","filing":"0001415889-25-003364","document":"form4-02072025_090202.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925003364/form4-02072025_090202.xml","form_type":"4"}},{"id":1282030,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-06T02:20:57.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2025, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":315000,"derivative":{"exercise_price":1.34,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0001415889-25-003173","document":"form4-02062025_020253.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925003173/form4-02062025_020253.xml","form_type":"4"}},{"id":1282029,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-06T02:20:57.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the \"2015 Plan\"), 2021 Equity Incentive Plan (the \"2021 Plan\") and 2023 Inducement Plan (the \"Inducement Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the \"Effective Date\"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":125000,"derivative":{"exercise_price":1.34,"expiration_date":"2034-01-28","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001415889-25-003173","document":"form4-02062025_020253.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925003173/form4-02062025_020253.xml","form_type":"4"}},{"id":1282028,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-06T02:20:57.000Z","date":"2025-02-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the \"2015 Plan\"), 2021 Equity Incentive Plan (the \"2021 Plan\") and 2023 Inducement Plan (the \"Inducement Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the \"Effective Date\"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":0,"derivative":{"exercise_price":2.41,"expiration_date":"2034-01-28","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001415889-25-003173","document":"form4-02062025_020253.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925003173/form4-02062025_020253.xml","form_type":"4"}},{"id":1282027,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-06T02:20:57.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":109000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the \"2015 Plan\"), 2021 Equity Incentive Plan (the \"2021 Plan\") and 2023 Inducement Plan (the \"Inducement Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the \"Effective Date\"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":109000,"derivative":{"exercise_price":1.34,"expiration_date":"2033-02-05","underlying":"Common Stock","underlying_shares":109000},"source":{"system":"sec-edgar","filing":"0001415889-25-003173","document":"form4-02062025_020253.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925003173/form4-02062025_020253.xml","form_type":"4"}},{"id":1282026,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-06T02:20:57.000Z","date":"2025-02-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":109000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the \"2015 Plan\"), 2021 Equity Incentive Plan (the \"2021 Plan\") and 2023 Inducement Plan (the \"Inducement Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the \"Effective Date\"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares vested or shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":0,"derivative":{"exercise_price":5.55,"expiration_date":"2033-02-05","underlying":"Common Stock","underlying_shares":109000},"source":{"system":"sec-edgar","filing":"0001415889-25-003173","document":"form4-02062025_020253.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925003173/form4-02062025_020253.xml","form_type":"4"}},{"id":1282025,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-06T02:20:57.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":364000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price of the stock option award is $1.34 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date. Under the terms of the stock option award repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends upon the earliest of (i) the date 12 months following the Effective Date; (ii) a Change in Control during the optionholder's Continuous Service (each as defined in the 2021 Plan or Inducement Plan, as applicable) with the Company or while the optionholder is an Eligible Participant (as defined in the 2015 Plan), as applicable; and (iii) 30 days prior to the option's original expiration date."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the \"2015 Plan\"), 2021 Equity Incentive Plan (the \"2021 Plan\") and 2023 Inducement Plan (the \"Inducement Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the \"Effective Date\"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4th of the shares underlying the option vested on October 11, 2023, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":364000,"derivative":{"exercise_price":1.34,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":364000},"source":{"system":"sec-edgar","filing":"0001415889-25-003173","document":"form4-02062025_020253.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925003173/form4-02062025_020253.xml","form_type":"4"}},{"id":1282024,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-06T02:20:57.000Z","date":"2025-02-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":364000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 3, 2025, pursuant to the terms of the Issuer's 2015 Stock Incentive Plan (the \"2015 Plan\"), 2021 Equity Incentive Plan (the \"2021 Plan\") and 2023 Inducement Plan (the \"Inducement Plan\"), the Issuer's Board of Directors approved a stock option award repricing, effective as of February 3, 2025 (the \"Effective Date\"). Except for the new exercise price (see footnote 5 below), all of the other terms of the stock option award remain unchanged. This transaction is exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/4th of the shares underlying the option vested on October 11, 2023, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":0,"derivative":{"exercise_price":3.77,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":364000},"source":{"system":"sec-edgar","filing":"0001415889-25-003173","document":"form4-02062025_020253.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925003173/form4-02062025_020253.xml","form_type":"4"}},{"id":1282023,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-06T02:20:57.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares underlying RSUs. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2025, subject to the Reporting Person's continued service as of each such date."}],"balance_after":132586,"source":{"system":"sec-edgar","filing":"0001415889-25-003173","document":"form4-02062025_020253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925003173/form4-02062025_020253.xml","form_type":"4"}},{"id":1282022,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-06T02:20:57.000Z","date":"2025-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":1353,"price":1.34,"value":1813.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units (\"RSUs\")."}],"balance_after":80086,"source":{"system":"sec-edgar","filing":"0001415889-25-003173","document":"form4-02062025_020253.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588925003173/form4-02062025_020253.xml","form_type":"4"}},{"id":1319874,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-12-31T21:15:13.000Z","date":"2024-12-27","kind":"sale","planned":true,"acquired":false,"shares":10334,"price":1.25,"value":12917.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024."}],"balance_after":81439,"source":{"system":"sec-edgar","filing":"0001415889-24-030316","document":"form4-12312024_041209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924030316/form4-12312024_041209.xml","form_type":"4"}},{"id":1371531,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-11-08T21:15:15.000Z","date":"2024-11-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":999,"price":0.86,"value":859.14,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":91773,"source":{"system":"sec-edgar","filing":"0001415889-24-026430","document":"form4-11082024_041107.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924026430/form4-11082024_041107.xml","form_type":"4"}},{"id":1375586,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-11-05T21:15:16.000Z","date":"2024-11-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1146,"price":0.8,"value":916.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":92772,"source":{"system":"sec-edgar","filing":"0001415889-24-026127","document":"form4-11052024_041111.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924026127/form4-11052024_041111.xml","form_type":"4"}},{"id":1437893,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-08T20:33:02.000Z","date":"2024-08-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":999,"price":0.87,"value":869.13,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":93918,"source":{"system":"sec-edgar","filing":"0001415889-24-020992","document":"form4-08082024_080858.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924020992/form4-08082024_080858.xml","form_type":"4"}},{"id":1440944,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-08-05T20:15:13.000Z","date":"2024-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1146,"price":0.94,"value":1077.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":94917,"source":{"system":"sec-edgar","filing":"0001415889-24-020738","document":"form4-08052024_040809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924020738/form4-08052024_040809.xml","form_type":"4"}},{"id":1492616,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-04T22:09:08.000Z","date":"2024-06-03","kind":"sale","planned":true,"acquired":false,"shares":14645,"price":1.39,"value":20356.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.31 to $1.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":96063,"source":{"system":"sec-edgar","filing":"0001415889-24-015450","document":"form4-06042024_100605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924015450/form4-06042024_100605.xml","form_type":"4"}},{"id":1524848,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-05-07T20:15:29.000Z","date":"2024-05-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":999,"price":1.75,"value":1748.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":110708,"source":{"system":"sec-edgar","filing":"0001415889-24-012460","document":"form4-05072024_040519.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924012460/form4-05072024_040519.xml","form_type":"4"}},{"id":1528502,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-05-03T20:15:35.000Z","date":"2024-05-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":1146,"price":1.77,"value":2028.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":111707,"source":{"system":"sec-edgar","filing":"0001415889-24-012159","document":"form4-05032024_040525.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924012159/form4-05032024_040525.xml","form_type":"4"}},{"id":1653643,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-08T22:10:38.000Z","date":"2024-02-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":1180,"price":2.32,"value":2737.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":112853,"source":{"system":"sec-edgar","filing":"0001415889-24-003041","document":"form4-02082024_100231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924003041/form4-02082024_100231.xml","form_type":"4"}},{"id":1665326,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-01T00:38:03.000Z","date":"2024-01-29","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":125000,"derivative":{"exercise_price":2.41,"expiration_date":"2034-01-28","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001415889-24-002104","document":"form4-02012024_120200.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924002104/form4-02012024_120200.xml","form_type":"4"}},{"id":1665325,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-02-01T00:38:03.000Z","date":"2024-01-29","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2024, subject to the Reporting Person's continued service as of each such date."}],"balance_after":114033,"source":{"system":"sec-edgar","filing":"0001415889-24-002104","document":"form4-02012024_120200.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000141588924002104/form4-02012024_120200.xml","form_type":"4"}},{"id":1746841,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-11-08T21:10:47.000Z","date":"2023-11-06","kind":"tax_withholding","planned":false,"acquired":false,"shares":999,"price":1.82,"value":1818.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units."}],"balance_after":51533,"source":{"system":"sec-edgar","filing":"0001209191-23-054692","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919123054692/doc4.xml","form_type":"4"}},{"id":1812109,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-09T20:31:41.000Z","date":"2023-08-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":999,"price":2.67,"value":2667.33,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units (\"RSUs\")."}],"balance_after":52532,"source":{"system":"sec-edgar","filing":"0001209191-23-045181","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919123045181/doc4.xml","form_type":"4"}},{"id":1898267,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-05-10T20:14:45.000Z","date":"2023-05-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":969,"price":4.14,"value":4011.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units (\"RSUs\")."}],"balance_after":53531,"source":{"system":"sec-edgar","filing":"0001209191-23-028458","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919123028458/doc4.xml","form_type":"4"}},{"id":2026633,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-02-08T21:23:55.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":109000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 6, 2023, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":109000,"derivative":{"exercise_price":5.55,"expiration_date":"2033-02-05","underlying":"Common Stock","underlying_shares":109000},"source":{"system":"sec-edgar","filing":"0001209191-23-007787","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919123007787/doc4.xml","form_type":"4"}},{"id":2026632,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-08T21:23:55.000Z","date":"2023-02-06","kind":"grant","acquired":true,"shares":54500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares underlying restricted stock units (\"RSUs\"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning February 6, 2023, subject to the Reporting Person's continued service as of each such date."}],"balance_after":54500,"source":{"system":"sec-edgar","filing":"0001209191-23-007787","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919123007787/doc4.xml","form_type":"4"}},{"id":2138383,"issuer":{"id":4763,"kind":"organization","name":"Vor Biopharma Inc.","symbol":"VOR"},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-10-12T20:24:41.000Z","date":"2022-10-11","kind":"grant","acquired":true,"shares":364000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares underlying the option vest on October 11, 2023, with the remainder vesting in equal monthly installments over 3 years, in each case subject to the Reporting Person's continued service as of each such date."}],"balance_after":364000,"derivative":{"exercise_price":3.77,"expiration_date":"2032-10-10","underlying":"Common Stock","underlying_shares":364000},"source":{"system":"sec-edgar","filing":"0001209191-22-053463","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817229/000120919122053463/doc4.xml","form_type":"4"}},{"id":2239830,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-06-07T21:00:32.000Z","date":"2022-06-03","kind":"tax_withholding","acquired":false,"shares":32667,"price":0.805,"value":26296.935,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 89,900 restricted stock units."}],"balance_after":57233,"source":{"system":"sec-edgar","filing":"0001104659-22-068995","document":"tm2217848-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922068995/tm2217848-1_4seq1.xml","form_type":"4"}},{"id":2334927,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2022-03-14T21:01:30.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":185900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on March 10, 2023, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":185900,"derivative":{"exercise_price":1.82,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":185900},"source":{"system":"sec-edgar","filing":"0001104659-22-033390","document":"tm229119-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922033390/tm229119-2_4seq1.xml","form_type":"4"}},{"id":2334926,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-14T21:01:30.000Z","date":"2022-03-10","kind":"grant","acquired":true,"shares":42900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on March 10, 2022, and which will vest and be settled in common stock as follows: (i) 14,300 shares on March 10, 2023, (ii) 14,300 shares on March 10, 2024 and (iii) 14,300 shares on March 10, 2025, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":89900,"source":{"system":"sec-edgar","filing":"0001104659-22-033390","document":"tm229119-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922033390/tm229119-2_4seq1.xml","form_type":"4"}},{"id":2364171,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-01T22:01:01.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":36000,"price":1.73,"value":62280.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.66 to $1.77 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":47000,"source":{"system":"sec-edgar","filing":"0001104659-22-028757","document":"tm227953-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922028757/tm227953-1_4seq1.xml","form_type":"4"}},{"id":2563645,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-20T21:29:34.000Z","date":"2021-09-16","kind":"sale","acquired":false,"shares":15968,"price":4.68,"value":74730.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.55 to $4.85 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":83000,"source":{"system":"sec-edgar","filing":"0001104659-21-117446","document":"tm2127534-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465921117446/tm2127534-2_4seq1.xml","form_type":"4"}},{"id":2587601,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-08-27T21:00:50.000Z","date":"2021-08-25","kind":"tax_withholding","acquired":false,"shares":9032,"price":3.98,"value":35947.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 25,000 restricted stock units"}],"balance_after":98968,"source":{"system":"sec-edgar","filing":"0001104659-21-110595","document":"tm2126037-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465921110595/tm2126037-1_4seq1.xml","form_type":"4"}},{"id":2825111,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2021-03-02T00:12:45.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":143000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":143000,"derivative":{"exercise_price":6,"expiration_date":"2031-02-25","underlying":"Common Stock","underlying_shares":143000},"source":{"system":"sec-edgar","filing":"0001140361-21-006738","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036121006738/form4.xml","form_type":"4"}},{"id":2825110,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-02T00:12:45.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 25,000 shares on August 25, 2021, (ii) 25,000 shares on February 25, 2022 and (iii) 25,000 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":108000,"source":{"system":"sec-edgar","filing":"0001140361-21-006738","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036121006738/form4.xml","form_type":"4"}},{"id":2825109,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-02T00:12:45.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 11,000 shares on February 25, 2022, (ii) 11,000 shares on February 25, 2023 and (iii) 11,000 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions."}],"balance_after":33000,"source":{"system":"sec-edgar","filing":"0001140361-21-006738","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036121006738/form4.xml","form_type":"4"}},{"id":3193894,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2020-03-26T21:01:21.000Z","date":"2020-03-24","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of these options vest on March 24, 2021, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":55000,"derivative":{"exercise_price":35.5,"expiration_date":"2030-03-24","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-20-038880","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465920038880/a4.xml","form_type":"4"}},{"id":3396396,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Stock Option (right to Buy)","published_at":"2019-10-07T23:18:42.000Z","date":"2019-10-07","kind":"grant","acquired":true,"shares":77630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of these options vest on October 2, 2020, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":77630,"derivative":{"exercise_price":15,"expiration_date":"2029-10-02","underlying":"Common Stock","underlying_shares":77630},"source":{"system":"sec-edgar","filing":"0001140361-19-018074","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036119018074/form4.xml","form_type":"4"}},{"id":3396395,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-10-07T23:18:42.000Z","date":"2019-10-07","kind":"purchase","acquired":true,"shares":200,"price":15,"value":3000.0,"ownership":{"direct":false,"nature":"By child"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose."}],"balance_after":200,"source":{"system":"sec-edgar","filing":"0001140361-19-018074","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036119018074/form4.xml","form_type":"4"}},{"id":3396394,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":83123,"kind":"person","name":"Attar Eyal C.","position":1,"cik":"0001789076","reported_name":"Attar Eyal C.","relationship":{"officer":true,"officer_title":"SVP, Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-10-07T23:18:42.000Z","date":"2019-10-07","kind":"purchase","acquired":true,"shares":200,"price":15,"value":3000.0,"ownership":{"direct":false,"nature":"By adult child"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose."}],"balance_after":200,"source":{"system":"sec-edgar","filing":"0001140361-19-018074","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036119018074/form4.xml","form_type":"4"}}]}